Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ND0612 in Parkinson's Disease with Motor Fluctuations
NCT02782481Phase 3Withdrawn
- Sponsor
- NeuroDerm Ltd.
- Start
- Aug 2016
- Primary completion
- Oct 2018
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ND0612 in Parkinson's disease (PD) (3 arms), sponsored by NeuroDerm Ltd. Primary endpoint: Change in mean percentage of OFF time during waking hours at 16 weeks. Planned start Aug 2016; status: withdrawn.
02
Drugs
ND0612
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02782481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02782481.